115 related articles for article (PubMed ID: 27343758)
1. 7-Ketocholesterol overcomes drug resistance in chronic myeloid leukemia cell lines beyond MDR1 mechanism.
Rosa Fernandes L; Stern AC; Cavaglieri RC; Nogueira FC; Domont G; Palmisano G; Bydlowski SP
J Proteomics; 2017 Jan; 151():12-23. PubMed ID: 27343758
[TBL] [Abstract][Full Text] [Related]
2. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
3. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
4. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines?
Rumjanek VM; Vidal RS; Maia RC
Biosci Rep; 2013 Nov; 33(6):. PubMed ID: 24070327
[TBL] [Abstract][Full Text] [Related]
6. Identification of galectin-1 as a novel mediator for chemoresistance in chronic myeloid leukemia cells.
Luo W; Song L; Chen XL; Zeng XF; Wu JZ; Zhu CR; Huang T; Tan XP; Lin XM; Yang Q; Wang JZ; Li XK; Wu XP
Oncotarget; 2016 May; 7(18):26709-23. PubMed ID: 27050374
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
[TBL] [Abstract][Full Text] [Related]
8. Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia.
Kuroda J; Yamamoto M; Nagoshi H; Kobayashi T; Sasaki N; Shimura Y; Horiike S; Kimura S; Yamauchi A; Hirashima M; Taniwaki M
Mol Cancer Res; 2010 Jul; 8(7):994-1001. PubMed ID: 20571063
[TBL] [Abstract][Full Text] [Related]
9. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of chlorpromazine antitumor activity by Pluronics F127/L81 nanostructured system against human multidrug resistant leukemia.
Mello JC; Moraes VW; Watashi CM; da Silva DC; Cavalcanti LP; Franco MK; Yokaichiya F; de Araujo DR; Rodrigues T
Pharmacol Res; 2016 Sep; 111():102-112. PubMed ID: 27265114
[TBL] [Abstract][Full Text] [Related]
11. Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells.
Lei H; Jin J; Liu M; Li X; Luo H; Yang L; Xu H; Wu Y
Leuk Res; 2018 Jan; 64():17-23. PubMed ID: 29149649
[TBL] [Abstract][Full Text] [Related]
12. A novel curcumin derivative which inhibits P-glycoprotein, arrests cell cycle and induces apoptosis in multidrug resistance cells.
Lopes-Rodrigues V; Oliveira A; Correia-da-Silva M; Pinto M; Lima RT; Sousa E; Vasconcelos MH
Bioorg Med Chem; 2017 Jan; 25(2):581-596. PubMed ID: 27908756
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a multidrug-resistant chronic myeloid leukemia cell line presenting multiple resistance mechanisms.
Daflon-Yunes N; Pinto-Silva FE; Vidal RS; Novis BF; Berguetti T; Lopes RR; Polycarpo C; Rumjanek VM
Mol Cell Biochem; 2013 Nov; 383(1-2):123-35. PubMed ID: 23877223
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells.
Baran Y; Ural AU; Gunduz U
Hematology; 2007 Dec; 12(6):497-503. PubMed ID: 17852433
[TBL] [Abstract][Full Text] [Related]
15. CR-LAAO antileukemic effect against Bcr-Abl(+) cells is mediated by apoptosis and hydrogen peroxide.
Burin SM; Ghisla S; Ouchida AT; Aissa AF; Coelho MG; Costa TR; Marsola AP; Pinto-Simões B; Antunes LM; Curti C; Sampaio SV; de Castro FA
Int J Biol Macromol; 2016 May; 86():309-20. PubMed ID: 26812110
[TBL] [Abstract][Full Text] [Related]
16. 4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines.
Lompardía SL; Díaz M; Papademetrio DL; Pibuel M; Álvarez É; Hajos SE
Invest New Drugs; 2017 Feb; 35(1):1-10. PubMed ID: 27718039
[TBL] [Abstract][Full Text] [Related]
17. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
18. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Carter BZ; Wang X; Shi X; Liu J
J Hematol Oncol; 2016 Nov; 9(1):129. PubMed ID: 27884201
[TBL] [Abstract][Full Text] [Related]
19. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
20. The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
Wang J; Hu J; Jin Z; Wan H
Leuk Res; 2016 Aug; 47():32-40. PubMed ID: 27244255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
